Investors - Publish Your Stock
Picks and Stock Profiles
Share your investor ideas!
Publish here today!
Security Sector Stocks ADVERTISEMENT
Featured Sponsors - To request more info on any of our featured
companies click here
*If you are interested in becoming a featured company for this portal please contact
email@example.com for a proposal.
Featured Homeland Security Content
What are the analysts saying?
Featured Biodefense Stocks at Investorideas.com
Aethlon Medical, Inc.
Aethlon Medical, Inc. (OTCBB:AEMD) Aethlon Medical is the developer of the Hemopurifier®, a first-in-class medical device designed to treat infectious disease. The Hemopurifier® provides real-time therapeutic filtration of infectious viruses and immunosuppressive particles, and is positioned to address the treatment of drug and vaccine resistant viruses. Additionally, the device holds promise in cancer care, as research studies have verified the Hemopurifier® is able to capture immunosuppressive particles secreted by tumors. The Hemopurifier® is designed to act both as a stand-alone therapeutic, and as an adjunct treatment to enhance clinical benefit of established therapies. Pre-clinical studies conducted by researchers representing leading government and non-government health organizations both in the United States and abroad have documented the effectiveness of the Hemopurifier® in capturing from circulation the viruses that constitute pandemic threats, including H5N1 Avian Influenza (bird flu), and Dengue Hemorrhagic Fever (DHF) from circulation. The company is conducting studies to support the use of the Hemopurifier® as a broad-spectrum treatment countermeasure against bioterror threats, including Smallpox, and Ebola, Marburg, and Lassa hemorrhagic fever. Regulatory and commercialization initiatives in the United States are presently focused on bioterror threats, while international initiatives are directed toward naturally evolving pandemic threats, and chronic infectious disease conditions including the Human Immunodeficiency Virus HIV) and Hepatitis-C (HCV). Aethlon has demonstrated safety of the Hemopurifier® in a 24-treatment human study at the Apollo Hospital in Delhi, India, and in an 18-treatment study at the Fortis Hospital, also located in Delhi. The company has submitted an investigational device exemption (IDE) to the U.S. Food and Drug Administration (FDA) to advance the Hemopurifier® as a broad-spectrum treatment countermeasure against category "A" bioterror threats.
PositiveID Corporation (NasdaqCM:PSID) develops and markets healthcare and information management products through its RFID-based diagnostic devices and identification technologies, and its proprietary disease management tools. PositiveID operates in two main divisions: HealthID and ID Security.
* Stocks are showcase advertising biotech companies on our site - Read disclaimers and Disclosure
Aeolus Pharmaceuticals, Inc (OTC:AOLS) is developing a platform of a new class of broad-spectrum, catalytic-antioxidant compounds that protect healthy tissue from the damaging effects of radiation. Its first compound, AEOL 10150, is being developed for oncology indications, where it is used in combination with radiation therapy. It is also being developed, with funding by the US Department of Health and Human Services, as a medical countermeasure against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus' strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150, including the contract with BARDA valued, with options, at up to $118.4 million, to efficiently develop the compound for use in oncology.
Aethlon Medical, Inc. (OTC: AEMD) creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers.
BRUKER Corporation (NasdaqGS: BRKR) is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial, diagnostics and applied analysis. CBRN ( Chemical, biological, radiological, and nuclear defense): Conventional and homemade CBRN weapons and Toxic Industrial Hazards are an ever present and complex threat that commanders in all military circles must deal with. We have a long and trusted relationship in defence and constantly strive to provide best in its class equipment to keep it that way. Our range of field proven detection systems have been specially developed to provide military users with reliable tools that enable effective warning and response.
Cepheid (NasdaqGS: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the Company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the Company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. The Cepheid GeneXpert® System makes biothreat agent detection possible in minutes — all from unprepared samples. This easy-to-use, automated and highly accurate real-time PCR instrument combines the ingenuity of more than 30 patents into a sophisticated genetic tool for first responders. A patented, disposable, cartridge test for anthrax is available now, and can be performed on-site — delivering critical answers in critical situations.
Cleveland BioLabs, Inc. (NasdaqCM:CBLI) is a clinical-stage biotechnology company leveraging deep mechanistic understanding of the cell death process, apoptosis, to develop a robust pipeline of compounds primarily focused on oncology applications and mitigation of radiation injury. The Company's lead compound is being developed as both a radiation countermeasure and a cancer treatment. The Company has two operating subsidiaries, Incuron, LLC, and Panacela Labs, Inc., and strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, the Children's Cancer Institute Australia and the Armed Forces Radiobiology Research Institute. Entolimod™ (CBLB502) Biodefense is in development as a countermeasure against death following total body irradiation. Acute radiation syndrome (ARS) results from radiation exposure, for which there are currently no FDA-approved treatments. Entolimod™ (CBLB502) is a recombinant protein that induces a spectrum of protective effects upon direct interaction and signaling via toll-like receptor 5 (TLR5), an innate immune system receptor. It has multiple advantages compared to agonists of other TLRs, including those that are currently under development for oncology applications, stemming from its unique mechanism of action. A few additional animal and human studies need to be completed prior to submitting a Biological License Application (BLA) for licensure with the FDA. The protocols for these remaining studies are being discussed with the FDA. The FDA granted Entolimod™ (CBLB502) both Fast Track and Orphan Drug status for reducing the risk of death following a potentially lethal dose of total body irradiation during or after a radiation disaster. The U.S. government provides funding to conduct biodefense research and support the development of drugs and vaccines as medical countermeasures against potential terrorist attacks. Both the Department of Health and Human Services and the Department of Defense procure and maintain medical stockpiles to respond to bioterrorist and emerging infectious disease outbreaks. Under a declared state of emergency, countermeasures may be procured for the Strategic National Stockpile under an Emergency Use Authorization prior to their full FDA licensure approval.
Dynasil Corporation of America (NasdaqGM:DYSL) develops and manufactures detection and analysis technology, precision instruments and optical components for the homeland security, medical and industrial markets. Combining world-class technology with expertise in research and materials science, Dynasil is commercializing products including dual-mode radiation detection solutions for Homeland Security and commercial applications, probes for medical imaging and sensors for non-destructive testing.
Electronic Sensor Technology ( OTC:ESNR ) has developed and patented a breakthrough chemical vapor analysis process. This process applies gas chromatography calculations and technology toward a wide variety of industries, including Homeland Security, Life Sciences, Chemical and Petrochemical, Food & Beverage and Environmental. The zNose® is the first electronic nose designed for security applications and can detect anything outside standard voc regulations. The chemical vapors and odors that are produced by explosives, chemical and biological hazards are identified using ultra-high speed gas chromatography.
Emergent BioSolutions, Inc. (NYSE:EBS) is a specialty pharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company provides the world’s only FDA-licensed anthrax vaccine to protect against anthrax disease, BioThrax®.
Inovio Pharmaceuticals, Inc (NYSE MKT:INO) is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal protection against known as well as new unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio's clinical programs include phase II studies for cervical dysplasia, leukemia and hepatitis C virus and phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. Using its novel synthetic DNA vaccine technology, Inovio has created the potential for a new generation of vaccines that may help overcome the challenges of many infectious diseases with unmet medical needs.We have developed SynCon® vaccines against malaria, foot-and-mouth disease (for animals), dengue fever, Chikungunya virus, and other tropical infectious diseases, some which pose potential risk for bioterrorism.
Luminex Corporation (NasdaqGM: LMNX) develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company's xMAP system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Biodefense: Open-architecture xMAP® technology allows simultaneous detection of bacterial, viral and toxin agents, in a highly flexible, multiplexed architecture capable of protein and nucleic acid assay formats. The xMAP suspension array technology enables multiplex identification of up to 500 analytes in a single reaction using small sample volumes. The microsphere technology platform offers expansion capability, wherein newly discovered agent threats could be added to an existing panel with relative ease by adding new microsphere sets coupled to specific detection moieties. In addition to high multiplexing, thousands of microspheres from each region are used to detect each target in a single mix, yielding significant improvements in statistical accuracy.
Medizone International, Inc. (OTC:MZEI) is engaged in initial production of its modular design AsepticSure® Decontamination Systems. Decontamination to the sterilization standard of >6 log (99.9999%) is obtainable within hospitals, airlines, cruise ships, long term care facilities, food processing plants, clean room manufacturing facilities, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures.
NanoLogix, Inc. (OTC: NNLX) is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing. Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity.
Novavax Inc. (NasdaqGS:NVAX) is a clinical-stage biopharmaceutical company creating vaccines to address a broad range of infectious diseases worldwide. Using innovative recombinant nanoparticle technology, as well as new and efficient manufacturing approaches, the company produces vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections. Novavax is committed to using its technology platform to create geographic-specific vaccine solutions and is therefore involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India, LG Life Sciences of Korea and PATH. Together, these organizations support Novavax' worldwide commercialization strategy and have the global reach to create real and lasting change in the biopharmaceutical field. The Company is in a research collaboration with the U.S. Department of Homeland Security to develop a virus-like particle (VLP) vaccine countermeasure to protect the United States from foot-and-mouth disease. Our world-class scientific team is using VLP technology to tackle influenza viruses - including avian strains that have the potential to cause a pandemic outbreak. Our team has created vaccine candidates that are in various phases of clinical testing designed to protect against various circulating strains of pandemic influenza including H1N1 and H5N1, as well as seasonal influenza. Our recombinant nanoparticle protein micelle technology targeted at RSV has been tested in various preclinical studies and has now advanced into clinical testing. Our vision is to control the spread of infectious diseases by using a unique single-use manufacturing system that allows for the rapid mass production of recombinant protein nanoparticle vaccines. Our goal is to be able to rapidly deliver a customized vaccine in the midst of a declared pandemic.
Pacific Biosciences of California, Inc. (NasdaqGS:PACB) offers the PacBio® RS II Sequencing System to help scientists solve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) Sequencing technology, the Company's products enable: targeted sequencing to more comprehensively characterize genetic variations; de novo genome assembly to more fully identify, annotate and decipher genomic structures; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. By providing access to information that was previously inaccessible, Pacific Biosciences enables scientists to increase their understanding of biological systems. Currently, our focus is on applications for clinical, basic and agricultural research, with potential uses in molecular diagnostics, drug discovery and development, food safety, forensics, biosecurity and biofuels.
PharmAthene, Inc. (NYSE MKT :PIP) was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical agents. PharmAthene's lead product development programs include: SparVax® - next generation recombinant protective antigen (rPA) anthrax vaccine; Recombinant BChE- novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents and Valortim® - fully human monoclonal antibody for the prevention and treatment of anthrax infection.
Pressure BioSciences, Inc. (OTC: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.
Protalix BioTherapeutics, Inc. (NYSE MKT : PLX) is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system, ProCellEx(R). Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012, by Israel's Ministry of Health in September 2012 and by the Brazilian National Health Surveillance Agency (ANVISA) in March 2013. It also has been approved in Uruguay. Marketing applications for taliglucerase alfa have been filed in additional territories as well. Protalix has partnered with Pfizer Inc. for the worldwide development and commercialization of taliglucerase alfa, excluding Israel, where Protalix retains full rights. Protalix's development pipeline also includes the following product candidates: PRX-102, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; PRX-105, a pegylated recombinant human acetylcholinesterase in development for several therapeutic and prophylactic indications, a biodefense program and an organophosphate-based pesticide treatment program; an orally-delivered glucocerebrosidase enzyme that is naturally encased in carrot cells, also for the treatment of Gaucher disease; pr-antiTNF, a similar plant cell version of etanercept (Enbrel(R)) for the treatment of certain immune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis; and others.
Sarepta Therapeutics, Inc. ( NasdaqGM:SRPT) is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta Therapeutics has collaborative agreements with the U.S. government for the advancement of its RNA-based technologies related to the development of antiviral agents targeting hemorrhagic viruses and other real-world emerging threats to public health, including the H1N1 pandemic influenza virus and other pathogenic outbreaks. Working in collaboration with the Transformational Medical Technologies program (TMT) of the Defense Threat Reduction Agency, a part of the U.S. Department of Defense, we have been engaged in the development of antiviral agents for Marburg and Ebola viruses. Also working in cooperation TMT, we have been involved in the development of RNA-based drug candidates targeting influenza viruses, including the pandemic H1N1 influenza virus. Sarepta has received funding from the U.S. government for a variety of other programs including Junín virus, Dengue virus, anthrax and ricin.
SIGA Technologies (NasdaqGM:SIGA) Communities in the United States and around the world face a serious but unmet need for drugs to protect against potentially catastrophic emerging viral pathogens and biological weapons of mass destruction. We are a pharmaceutical company specializing in the development and commercialization of pharmaceutical solutions for some of the most lethal disease-causing pathogens in the world - smallpox, Ebola, dengue, Lassa fever and other dangerous viruses. Our business is to discover, develop, manufacture and successfully commercialize drugs to prevent and treat these high-priority threats. Our mission is to disarm dreaded viral diseases and create robust, modern biodefense countermeasures.
Soligenix, Inc. (OTC:SNGX) is a clinical stage biopharmaceutical company developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics. Through its BioDefense Division, Soligenix is developing countermeasures pursuant to the Biomedical Advanced Research and Development Authority (BARDA) Strategic Plan of 2011-2016 for inclusion in the US government's Strategic National Stockpile. Soligenix's lead biodefense products in development are a recombinant subunit vaccine called RiVax™, which is designed to protect against the lethal effects of exposure to ricin toxin and VeloThrax™, a vaccine against anthrax exposure. RiVax™ has been shown to be well tolerated and immunogenic in two Phase 1 clinical trials in healthy volunteers. Both RiVax™ and VeloThrax™ are currently the subject of a $9.4 million National Institute of Allergy and Infectious Diseases (NIAID) grant supporting development of Soligenix's new vaccine heat stabilization technology known as ThermoVax™. Soligenix is also developing OrbeShield™ for the treatment of gastrointestinal acute radiation syndrome (GI ARS) under a $600,000 NIAID Small Business Innovation Research (SBIR) grant. OrbeShield™ has previously demonstrated statistically significant preclinical survival results in two separate canine GI ARS studies funded by the NIH.
STERIS Corporation (NYSE:STE) The mission of STERIS Corporation is to provide a healthier today and safer tomorrow through knowledgeable people and innovative infection prevention, decontamination and health science technologies, products and services. The Company has approximately 6,000 dedicated employees around the world working together to supply a broad array of solutions by offering a combination of equipment, consumables and services to healthcare, pharmaceutical, industrial and government Customers. Biodefense: STERIS’s non-condensing VHP® and mVHP® gaseous decontamination technologies are scalable from small chambers for portable sensitive equipment to land vehicles, cargo and tactical aircraft, and building interiors. To address the many applications of VHP and mVHP decontamination, STERIS has developed a diverse family of delivery systems.
TapImmune Inc. ( OTC:TPIV E ) is a clinical-stage immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. TapImmune's immunotherapy technologies are also aimed at the prevention of emerging viral pathogens for pandemics and biodefense.
Trius Therapeutics Inc (NasdaqGM:TSRX) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections. The Company's lead investigational drug, tedizolid phosphate, is a novel antibiotic in Phase 3 clinical development for the treatment of serious gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). Trius has partnered with Bayer HealthCare for the development and commercialization of tedizolid phosphate outside of the U.S., Canada and the European Union. In addition to the Company's tedizolid phosphate clinical program, Trius has initiated Investigational New Drug (IND) enabling studies for its Gyrase-B development candidate with potent activity against Gram-negative bacterial pathogens including multi-drug resistant strains of E. coli,Klebsiella, Acinetobacter and Pseudomonas. Trius is working with Lawrence Livermore National Laboratories (LLNL) to develop a new class of antibacterial agents that target the bacterial cell wall enzyme MurB. This program is funded by a contract from the Defense Threat Reduction Agency (DTRA) through the research stage, subject to the achievement of certain milestones. In this program, Trius and LLNL apply structure-based drug discovery technologies to design novel antibacterial agents with spectrum on important commercial and biodefense Gram-negative pathogens. Using the FAST technology, Trius has shown that inhibition of MurB leads to synergy with beta-lactam antibiotics and in particular with cephalosporins. Consequently, MurB-based antibacterial agents might lead to commercially important combination drugs.
Versar Inc (AMEX: VSR) headquartered in Springfield, Virginia, is a publicly traded global project management company providing sustainable value oriented solutions to government and commercial clients in the construction management, environmental services, munitions response, and professional services market areas. Versar provides tailored and secure solutions in harsh environments and offers specialized abilities in Rapid Response, Classified Projects, and Hazardous Material Management.